Learn what’s not true — and what is — when it comes to bipolar disorder, with information from experts, backed by data from ...

Pedmark significantly reduces cisplatin-induced hearing loss in pediatric and AYA patients with non-metastatic solid tumors. The trial confirmed Pedmark's non-interference with cisplatin's antitumor ...

Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.

Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old ...

Ofsted has warned of “multiple missed opportunities” to identify pupils’ SEND needs and arrange support to keep them in ...

Every year, on the 1st of December, we join the world to observe World AIDS Day, not as a mere formality but as an opportunity to remember and strengthen our commitment to honouring lives lost. The ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

Greece’s mental-health system for adolescents is in deep crisis, as highlighted by data from a recent intervention by the ...

Children are presenting with complex, sometimes co-occurring, psychiatric disorders. Pediatric primary care providers play a ...

Leicester has a shortfall in specialist education provision for children with SEND, an inspection has found, with one parent ...